Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Urology Associates

Neither a doctor nor a teaching hospital

Research payments

$2,358,349

99 payments

Through program year 2025, Urology Associates is reported as receiving $2,358,349 in research payments, across 99 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $126,166 3
2024 Research $886,645 7
2023 Research $851,334 15
2022 Research $267,592 12
2021 Research $40,022 9
2020 Research $109,064 46
2019 Research $77,525 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,031,022 25 payments
  2. Dendreon Pharmaceuticals LLC $121,298 24 payments
  3. Clovis Oncology, Inc. $76,450 33 payments
  4. Veru Inc. $71,035 5 payments
  5. Epizyme, Inc., $20,726 4 payments
  6. Urogen Pharma, Inc. $9,700 1 payment
  7. Allergan Inc. $8,500 1 payment
  8. AstraZeneca Pharmaceuticals LP $8,250 2 payments
  9. GlaxoSmithKline, LLC. $8,050 2 payments
  10. Myriad Genetic Laboratories, Inc. $2,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 $989,274 7 payments
  2. A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy MK-6482-022 $853,686 3 payments
  3. Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) $76,450 33 payments
  4. Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $71,035 5 payments
  5. A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph $66,420 1 payment
  6. Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma $60,136 9 payments
  7. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $55,225 4 payments
  8. A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $49,036 14 payments
  9. A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph $48,732 1 payment
  10. A Phase 1B/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer $20,726 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record